To include your compound in the COVID-19 Resource Center, submit it here.

Aerie's Rhopressa wins FDA panel votes

An FDA advisory committee voted 9-1 on Friday that the efficacy of Rhopressa netarsudil 0.02% from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shown in clinical

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE